Parents See Cancer Prevention as
Best Reason for HPV Vaccine
An online survey of 1,177 parents of children ages
11-17 in the U.S. found that these adults believe
cancer prevention is the best reason for a child to
receive the human papillomavirus (HPV) vaccine.
The vaccine can prevent HPV-related cancers of
the anus, cervix, penis, vagina, head and neck.
The researchers conclude that having health
care providers emphasize the vaccine’s ability to
prevent cancer could help increase vaccination
rates. As of 2016, only about one-third of
13-year-olds in the U.S. had been vaccinated.
LEARN MORE IN THE JULY 2018 CANCER
EPIDEMIOLOGY, BIOMARKERS & PREVENTION.
SOURAV BANDYOPADHYAY ON NEW WAYS
TO THINK ABOUT CHEMOTHERAPY
Most cancer patients will have a treatment plan that includes chemotherapy. Many of the chemotherapy drugs they receive are likely to have been com-
monly used for decades. These treatments continue to be
offered because they often can extend people’s lives. But it’s
possible that there are ways to use them more effectively.
Sourav Bandyopadhyay, a computational and molecular biologist at the
Helen Diller Family Comprehensive Cancer Center at the University
of California, San Francisco, studies the ways biological networks
inside cancer cells affect how tumors respond to cancer treatments.
Bandyopadhyay and his team published a study in the April 17, 2018, Cell
Reports that suggests analyzing the genetics of a patient’s tumor could
potentially lead to a more targeted approach to chemotherapy. Cancer
Today spoke with Bandyopadhyay about his research and why it is important to rethink traditional ways of using chemotherapy.
Q: What is the framework for your research?
A: Rather than focusing on one gene at a time, we apply a systematic and
data-driven approach to try to understand patterns and rules for drug
response in patients. We are trying to move away from studying the effect
of one gene and one pathway to a total understanding of the effect of